showed that anti-HER2/neu antibodies are necessary and sufficient for protection from tumor challenge, a temporary necessity for CD4+ T cells for 36-48h after immunization to provide help for B cells, and no requirement for CD8+ T cells at all. The gene discussed is ERBB2; the disease is neoplasm.